openPR Logo
Press release

Lung Cancer Therapeutics Market Projected to Grow Steadily During (2015-2025)

08-30-2017 02:20 PM CET | Health & Medicine

Press release from: Future Market Insights

Lung Cancer Therapeutics Market Projected to Grow Steadily

Lung cancer is a malignant tumor characterized by uncontrolled growth of cell tissues in the lung. Itis the second most commonly diagnosed and has the highest mortality rate of all cancers in both men and women. American Lung Association has estimated that around 224,210new cases were diagnosed with lung cancer in the American region that accounts for approximately 13% of all the cancer cases diagnosed. Thus, with the rise in incidence rate of lung cancer, the demand for therapeutics is also expected to grow during the study period.

Based on the cancer cell types, lung cancer is broadly segmented as small cell lung cancer and non-small cell lung cancer (NSCLC). NSCLC segment accounts for approximately 80 to 90% of all lung cancers. Based on the cell shape and size, NSCLC is further divided to three subtypes, they are adenocarcinoma,large-cell carcinoma and squamous cell carcinoma. These NSCLC’s are primarily treated with the surgeries, at the same time chemotherapy is increasingly used for both pre-operative and post-operative treatment of the patients. The treatment options available for the NSCLC includesurgery, radiation therapy andchemotherapy. As per the American Cancer Society, it was estimated that in the United States approximately 195,000 peopleare suffering from NSCLC every year and the number of deaths from NSCLC areapproximately 135,000. The top five global brands that are commercially available in the market are Avastin, Tarceva, Alimta, Gemzar and Taxotere. Thus, all the above mentioned factors collectively drive the growth of the global lung cancer therapeutics market.

Request For Report Sample@ http://www.futuremarketinsights.com/reports/sample/rep-gb-422

The global lung cancer therapeutics market can be segmented as follows:

By Drugs

Hycamtin

Taxotere

Gemzar

Alimta

Iressa

Avastin

Tarceva

Pipeline Drugs

Xalkori

Afatinib

Dacomitinib

ARQ 197

Talactoferrin

Increasing incidences of lung cancer due to rising smoking population is one of the major factors driving the growth of lung cancer therapeutics market. The risk of lung cancer is tenfold higher in smokers as compared to non-smokers. In addition, launch of premium priced drugs, new innovative radiation therapies coupled with rising incidences of NSCLC are the major driving factors for the growth of lung cancer therapeutics market. However, genericization of the major drugs might restrict the growth of this market.

Geographically, North America and Europe dominates the global lung cancer therapeutics market. According to Lung Disease Research Funding, approximately 75,000 people in the U.S. die because of lung injury every year. The United States is the largest market for NSCLC owing to the high incidence rate, rise in aging population. In addition, with advent of new treatment therapies such as targeted drug therapy, stereotacticsare aiding patient population. Europe accounts to be the largest market after North America.While, Asia-Pacific countries such as India and China, South East Asia are the emerging regions for the global lung cancer therapeutics market due to high prevalence of this diseasecoupled with increasing healthcare awareness.

Visit For TOC@ http://www.futuremarketinsights.com/toc/rep-gb-422

Players are adopting various strategies to expand their product portfolio and increase its geographical presence. New product development, agreements and collaborations and acquisitions are some of the important strategies adopted by the players in the global lung cancer therapeutics market. The prominent leading players of this market include AstrazenecaPlc, Eli Lilly and Company, GlaxoSmitKline, Hoffman-La Roche, BoehringerIngelheim GmbH, Pfizer Inc.,Sanofi-Aventis, among others.

ABOUT US:
Future Market Insights (FMI) is a leading market intelligence and consulting firm. We deliver syndicated research reports, custom research reports and consulting services, which are personalized in nature. FMI delivers a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights, an aerial view of the competitive framework, and future market trends.

CONTACT:
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
F: +1-845-579-5705
Email: sales@futuremarketinsights.com
Website: www.futuremarketinsights.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Lung Cancer Therapeutics Market Projected to Grow Steadily During (2015-2025) here

News-ID: 691651 • Views:

More Releases from Future Market Insights

Fresh Water Generator Market Strengthens as Marine Operators Prioritize Autonomy and Cost Control
Fresh Water Generator Market Strengthens as Marine Operators Prioritize Autonomy …
The fresh water generator market is projected to expand from USD 1,120.0 million in 2026 to USD 2,122.2 million by 2036, registering a CAGR of 6.60% over the forecast period. Growth is driven by the rising need for onboard water security, longer voyage durations, and increasing pressure on operators to reduce dependence on port-based freshwater bunkering. Fresh water generators sit at the intersection of operational autonomy and lifecycle cost discipline for
Zonal Harness Systems Market to Reach USD 5.2 Billion by 2036 as OEMs Redesign Vehicle Electrical Architectures
Zonal Harness Systems Market to Reach USD 5.2 Billion by 2036 as OEMs Redesign V …
The global zonal harness systems market is gaining strong momentum as automotive OEMs accelerate the transition toward centralized, software-defined electrical architectures. The market is forecast to expand from USD 2.0 billion in 2026 to USD 5.2 billion by 2036, registering a compound annual growth rate (CAGR) of 10.0% over the forecast period. Unlike traditional wiring architectures, zonal harness systems reorganize electrical distribution around physical vehicle zones rather than individual functions. This
SiC Traction Modules Market Forecast and Outlook 2026 to 2036
SiC Traction Modules Market Forecast and Outlook 2026 to 2036
The global SiC traction modules market is expected to expand from USD 5.5 billion in 2026 to USD 22.3 billion by 2036, registering a strong CAGR of 15.0%. Beyond headline growth, the market represents a structural shift in electric powertrain design. SiC traction modules are no longer viewed as optional performance upgrades but as foundational infrastructure for next-generation EV platforms, particularly those adopting high-voltage architectures. Economic exposure in this market is
Global Battery Swap Hardware Market Poised for Sustained Growth Through 2036
Global Battery Swap Hardware Market Poised for Sustained Growth Through 2036
The global Battery Swap Hardware Market is entering a phase of steady, infrastructure-led expansion as electric mobility operators prioritize uptime, utilization efficiency, and scalable energy replenishment models. Global demand for battery swap hardware is forecast to rise from USD 2.5 billion in 2026 to USD 9.3 billion by 2036, expanding at a compound annual growth rate (CAGR) of 14.0% over the forecast period. Market expansion is being driven primarily by fleet-based

All 5 Releases


More Releases for NSCLC

NSCLC Treatment Market to Reach USD 55.30B by 2035
Non-Small Cell Lung Cancer Treatment Market: Growth Drivers, Innovation, and the Future of Lung Cancer Care The Non-Small Cell Lung Cancer (NSCLC) Treatment Market is undergoing a profound transformation as advances in diagnostics, targeted therapies, and immuno-oncology redefine how lung cancer is managed globally. NSCLC accounts for nearly 85% of all lung cancer cases, making it the most prevalent and commercially significant segment of the lung cancer therapeutics market. Historically, NSCLC was
NSCLC Patient Insights You Can't Afford to Ignore! A DelveInsight Case Study - H …
DelveInsight, a global leader in healthcare market intelligence and consulting, has successfully partnered with a top-tier biopharmaceutical company specializing in oncology to provide an advanced epidemiology forecasting analysis of Non-Small Cell Lung Cancer (NSCLC). This comprehensive study focused on biomarker-specific segmentation to support strategic drug development, identify target patient populations, and optimize market access planning across global markets. With the increasing complexity of NSCLC treatment, biomarker-driven therapies have emerged as a
Huateng Pharma Supplies Intermeidates of Pemetrexed Against NSCLC
Pemetrexed disodium is a drug successfully developed by Eli Lilly in the United States for the treatment of tumors, patent protection to January 2017. Pemetrexed disodium is a multi-targeted anti-folate agent with a core pyrrolopyrimidine moiety in its structure. It is a dual inhibitor of nucleotide synthase/dihydrofolate reductase, which inhibits cell replication by disrupting the normal process of folate-dependent metabolism in cells and simultaneously blocking three different enzyme targets critical
NSCLC Market Global Industry Analysis and Forecast Till 2027
Any type of epithelial lung cancer that isn't small cell lung cancer is referred to as NSCLC (SCLC). Squamous cell carcinoma, large cell carcinoma, and adenocarcinoma are the most common kinds of NSCLC, although there are several more types that are less common, and all types can occur in atypical histologic variants. Request Sample Copy of this Report: https://www.infinitybusinessinsights.com/request_sample.php?id=562904 Top Key Players Included in This Report: Merck KGa, Roche, Nlyte, Taxotere,
Targeted Drugs for NSCLC Market Size by 2025: QY Research
Global Targeted Drugs for NSCLC market report is first of its kind research report that covers the overview, summary, market dynamics, competitive analysis, and leading player’s various strategies to sustain in the global market. This report covers five top regions of the globe and countries within, which shows the status of regional development, consisting of market value, volume, size, and price data. Apart from this, the report also covers detail
"NSCLC - Market Outlook and Competitive Landscape Report 2015 – 2030 "
Report Snapshot: NSCLC is the most common form of lung cancer, accounting for approximately 85% of all types and subtypes of lung cancer. It grows and spreads more slowly than small cell lung cancer. Early stage disease is associated with uncommon specific symptoms; hence roughly ~50% to 73% of cases are not being diagnosed until the disease is at an advanced stage when the chances for cure or significant patient benefit